Findings from the post-hoc analysis of LIBERTY-CD study indicates efficacy of ZYMFENTRA® (subcutaneous infliximab) regardless ...

After being told he might not walk for two years, the longtime Little League football coach fought through treatment to ...

While documenting life on Hawaii’s Big Island, photographer Josh Cogan follows one man’s path toward reconnection—where food, ...

The good news is that, with significant late-stage pipeline activity, new early-stage projects, and continued strong ...

Nipocalimab is the first FcRn blocker approved in both adult and adolescent gMG patients aged 12 and older who are anti-AChR or anti-MuSK antibody-positive ...

The thought 'no-one is accountable' for the death of Helen Holland, the 81-year-old hit by the Duchess of Edinburgh's royal ...

National Geographic photographer Josh Cogan captures the quiet power of Hawaii’s ocean life, revealing how resilience shows ...

Getting treatment within one week of a serious head injury can reduce the risk of developing Alzheimer's disease by up to 41% ...

The two neurodegenerative diseases could not appear more different. Amyotrophic lateral sclerosis (ALS), sometimes called Lou ...

Biomedical research that began at the University of Virginia School of Medicine has yielded a much-needed new treatment for ...

The U.S. Food and Drug Administration has approved Novartis' gene therapy for patients with a rare muscle disorder, the drugmaker said on Monday.

AstraZeneca’s IMFINZI® (durvalumab) in combination with standard-of-care FLOT chemotherapy (fluorouracil, leucovorin, oxaliplatin, and docetaxel) has been approved in the US for the treatment of adult ...